论文部分内容阅读
1)新药应用面临的尴尬目前,全球都在致力于研发新的降糖药,尤其是不同于已有降糖药物的作用机制的新途径降糖药。但是,这类研发工作不仅进展缓慢且耗资巨大,现在新药的审批流程也越来越严格。此外,新药的长期安全性和有效性都有待临床应用的进一步证实。更让临床医生和患者感到尴尬的是,这类新药基本上都是进口药,价格往往要高出老药数倍甚至数十倍,而且大多不在医保范围内,所以大多数
1) embarrassment of new drug application Currently, the world are committed to the development of new hypoglycemic agents, especially different from the existing mechanism of hypoglycemic drugs, a new way of hypoglycemic agents. However, this kind of research and development work is not only slow and costly, but the approval process of new drugs is now more and more strict. In addition, the long-term safety and effectiveness of new drugs have yet to be further confirmed by clinical application. More embarrassing to clinicians and patients is that these new drugs are basically imported drugs, the price is often higher than the old drug several times or even several times, and most are not covered by the medical insurance, so most